StockData

Biofrontera vs SIGA Technologies

BFRI and SIGA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BFRI and SIGA compare

SIGA Technologies is the larger company, worth 19 times as much as Biofrontera ($197M against $10.4M).

Biofrontera grew revenue faster over the last twelve months (29.8% versus −69.6% for SIGA Technologies).

SIGA Technologies keeps more of each dollar of sales as profit, with a net margin of 1.3% compared with −12.7% at Biofrontera.

SIGA Technologies pays a dividend yielding 21.9%; Biofrontera does not pay one.

SIGA Technologies scores higher on the StockData Score (14 against 9 for Biofrontera), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBFRISIGA
Size and price
Market cap$10.4M$197M
Share price$0.700$2.74
Change, 1 year−28.1%−55.9%
Change, 5 years−98.7%−70.4%
Beta (5Y)0.971.08
Employees9249
StockData Score
Total score914 (better)
Valuation score13 (better)
Growth score2 (better)0
Performance score22
Health score46 (better)
Dividend score03 (better)
Valuation
P/S0.2× (better)3.8×
P/B–1.2×
FCF yield−53.4%–
Fair value–$6.01
Margin of safety–54.4%
Growth
Revenue growth (TTM)29.8% (better)−69.6%
Revenue growth, 5Y average17.2% (better)−5.4%
Net income growth (TTM)–−99.1%
EPS growth (TTM)–−100%
EPS growth, 5Y average–−14.7%
Profitability
Gross margin–54.0%
Operating margin−14.1% (better)−14.2%
Net margin−12.7%1.3% (better)
FCF margin−11.5%–
Return on equity–0.37%
Return on invested capital–−15.0%
Financial health
Debt / equity–0.00
Current ratio0.7824.57 (better)
Altman Z-score−7.8013.18 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Dividend yield–21.9%
Payout ratio–6325%
Years of dividend growth–0
Shareholder yield0.00%21.9% (better)
Ownership
Held by institutions18.6%48.5%
Held by insiders23.6%1.9%
Short interest, % of float1.7%5.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.